EQS-News

LPKF makes a solid start to the 2024 financial year - Seite 2

The CellShepherd has been commercially available in the ARRALYZE division since February. With this innovative biotech tool, LPKF aims to revolutionize single cell-based analysis in biomedicine and various life science areas such as personalized medicine. Market interest is high and further progress has already been made with prospective customers.

CEO Klaus Fiedler is convinced that LPKF has outstanding products in all business segments. The primary goal is to market these products faster and more efficiently in order to drive growth. Fiedler emphasizes: "We are aware that we must continuously optimize our cost structures in order to deliver profitable growth. The first operational steps to increase efficiency have already been taken and more willfollow.”  In addition, the Management Board will work closely with an external consultant to identify structural improvement opportunities, which will start to be effective with regard to profitability and working capital in the second half of this year.

In the current second quarter, the Management Board expects consolidated sales of EUR 28 - 33 million and adjusted EBIT* of between EUR -3 and 2 million.

For the 2024 financial year, as previously communicated LPKF expects consolidated revenue of EUR 130 - 140 million and an adjusted EBIT margin* of between 4% and 8%.

In the medium term, as already communicated, LPKF aims to achieve an attractive single-digit growth rate for its core business. In addition to the core business, the new business initiatives in the semiconductor, display and biotechnology markets are expected to contribute a total sales in the low three-digit million euro range in the medium term. Based on the growth in sales and the resulting economies of scale, the Management Board aims to achieve an attractive double-digit EBIT margin for the LPKF Group in the coming years.

The quarterly report is available in German and English at  https://www.lpkf.com/en/investor-relations/publications/financial-reports
 

*Adjusted EBIT is EBIT adjusted for restructuring and severance costs and changes in the long-term incentive (LTI) due to fluctuations in the performance factor or the share price. LPKF expects these costs to amount to 0.5 – 1.5% of revenue in the 2024 financial year. Adjusted EBIT is reported in order to be able to compare operating profitability between periods by eliminating special items.